|
Psychiatric diagnosis
|
|
Schizophrenia
|
20 (32.9%)
|
5 (55.5%)
|
15 (28.8%)
| |
|
Schizophreniform disorder
|
26 (42.6%)
|
1 (11.1%)
|
25 (48.1%)
| |
|
Brief psychotic disorder
|
10 (16.4%)
|
1 (11.1%)
|
9 (17.2%)
|
0.10
|
|
Cannabis-induced psychosis
|
3 (4.9%)
|
2 (22.2%)
|
1 (1.9%)
| |
|
Delusional psychosis
|
1 (1.6%)
|
0 (0%)
|
1 (1.9%)
| |
|
Psychotic disorder not otherwise specified
|
1 (1.6%)
|
0 (0%)
|
1 (1.9%)
| |
|
PANSS total score
|
99.5 ± 20.6
|
101.6 ± 20.5
|
99.1 ± 20.8
|
0.65
|
|
PANSS positive score
|
25.1 ± 6
|
27 ± 6.3
|
24.8 ± 6
|
0.43
|
|
PANSS negative score
|
24.3 ± 9.3
|
25.7 ± 9.8
|
24 ± 9.3
|
0.56
|
|
GAF score
|
32.4 ± 8
|
30 ± 5.6
|
33.5 ± 8.3
|
0.28
|
|
Duration of untreated psychosis (weeks)
|
39.6 ± 63.7
|
28.6 ± 35.2
|
41.5 ± 87.4
|
0.45
|
|
Antipsychotic treatment
|
|
First-generationantipsychotic
|
25(41%)
|
4 (44.4%)
|
21 (40.4%)
| |
|
Second-generationantipsychotic
|
19 (31.1%)
|
2 (22.2%)
|
17 (32.7%)
|
0.84
|
|
Co-treatment of first- and second-generation antipsychotics
|
17 (27.8%)
|
3 (33.3%)
|
14 (26.9%)
| |
|
Chlorpromazine equivalent
|
619.8 ± 419.8 mg
|
914.0 ± 629.8 mg
|
568.8 ± 356.6 mg
|
0.16
|
|
Simpson Angus scale score
|
3.8 ± 3.2
|
4.3 ± 2.6
|
3.7 ± 3.
|
0.37
|
|
Duration of hospitalization (days)
|
29.1 ± 16.6
|
43.3 ± 15.5
|
26.7 ± 15.6
|
0.005
|
